1. Protein Expression of Matriptase and its Cognate Inhibitor HAI-1 in Human Prostate Cancer
- Author
-
Jens C. Eickhoff, Wei Huang, David Frazier Jarrard, Miranda Warren, Matthew Twohig, Thomas Pier, and Chen-Yong Lin
- Subjects
Male ,PCA3 ,Pathology ,medicine.medical_specialty ,Histology ,Prostate Diseases ,Proteinase Inhibitory Proteins, Secretory ,Pathology and Forensic Medicine ,Automation ,Prostate cancer ,Prostate ,medicine ,Humans ,Matriptase ,Diagnosis, Computer-Assisted ,Neoplasm Metastasis ,Cell Proliferation ,Tissue microarray ,biology ,business.industry ,Serine Endopeptidases ,Prostatic Neoplasms ,Cancer ,Epithelial Cells ,Hyperplasia ,medicine.disease ,Medical Laboratory Technology ,medicine.anatomical_structure ,Tissue Array Analysis ,Disease Progression ,Cancer research ,biology.protein ,business - Abstract
Recent studies have suggested that matriptase, a transmembrane serine protease and its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1) are important in the progression of many cancers. Limited quantitative data are available on these proteins in prostate cancer. To validate the roles of matriptase and HAI-1 in prostate cancer and its progression, a prostate cancer tissue microarray was constructed. The tissue microarray includes 41 localized prostate cancers (Pca_local), 18 aggressive prostate cancers, 18 metastatic prostate cancers, 24 benign prostate hyperplasias, 18 high-grade intraepithelial neoplasias (HGPIN), and 41 benign prostate tissues. The cellular expression levels of matriptase and HAI-1 were quantified using automated quantitative analysis. We found that matriptase expression levels were significantly higher in Pca_local (P
- Published
- 2009